Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An interventional, single arm, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF)

Next Previous
Trial Profile

An interventional, single arm, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 18 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APZ 2 (Primary)
  • Indications Liver failure
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors RHEACELL

Most Recent Events

  • 09 Nov 2021 Status changed from active, no longer recruiting to discontinued.
  • 26 Aug 2021 Status changed from recruiting to active, no longer recruiting.
  • 11 Apr 2021 trial has been discontinued in Germany and Austria (global end of the trial 2021-03-26) as per European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top